Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma-Reference-Cited by-同舟云学术

Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma

Published:2014-02-06 Issue:12 Volume:49 Page:1578-1587
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Arizumi Tadaaki,Ueshima Kazuomi,Takeda Haruhiko,Osaki Yukio,Takita Masahiro,Inoue Tatsuo,Kitai Satoshi,Yada Norihisa,Hagiwara Satoru,Minami Yasunori,Sakurai Toshiharu,Nishida Naoshi,Kudo Masatoshi

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/content/pdf/10.1007/s00535-014-0936-0.pdf

Reference15 articles.

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.

2. Llovet JM, Ricci S, Mazzaferro V, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

3. Sakurai T, Kudo M. Signaling pathways governing tumor angiogenesis. Oncology. 2011;81:24–9.

4. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both RAF and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7:3129–40.

5. Rini BI. Sorafenib. Expert Opin Pharmacother. 2006;7:453–61.

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lenvatinib or Sorafenib Treatment Causing a Decrease in Skeletal Muscle Mass, an Independent Prognostic Factor in Hepatocellular Carcinoma: A Survival Analysis Using Time-Varying Covariates;Cancers;2023-08-23

2. RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis;BMJ Open;2022-06

3. Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version);Hepatology Research;2022-02-22

4. Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib;Cancer Imaging;2022-01-04

5. Response Evaluation Criteria in Cancer of the Liver (RECICL 2021 revised version);Kanzo;2021-12-01